Kenneth Carl Anderson

USPTO Granted Patents = 38 (Patent Applications = 18)

CIPO Patents = 6 (Patent Applications = 6)

EPO Patents = 9 (Patent Applications = 17)

Average Co-Inventor Count = 3.5

ph-index = 6

Forward Citations = 136(Granted Patents)

Location History:

Port Orchard, WA (US) (1995)
Conneaut, OH (US) (1996)
Wallesley, MA (US) (2008)
Wellesley, MA (US) (2006 - 2024)

Company Filing History:

30 out of 1,206

Dana-farber-cancer Institute Inc.

The General Hospital Corporation

patents

4. 3 out of 35

Acetylon Pharmaceuticals, Inc.

patents

5. 2 out of 836

University of Arkansas

patents

6. 2 out of 5

Fondazione Centro San Raffaele

Triphase Research and Development I Corp.

Celgene International Ii Sarl

patents

12. 1 out of 850

Millennium Pharmaceuticals Limited

patents

13. 3 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2025

Loading Chart...

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12448429 - T cell receptors specific to b-cell maturation antigen for treatment of cancer (2025-10-21),

2. 12109266 - Modulating gabarap to modulate immunogenic cell death (2024-10-08),

3. 12053468 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereof (2024-08-06),

4. 12005073 - Methods for modulating regulatory T cells, regulatory b cells, and immune responses using modulators of the april-taci interaction (2024-06-11),

5. 11802132 - Small molecules for inducing selective protein degradation and uses thereof (2023-10-31),

6. 11702402 - Small molecules that block proteasome-associated ubiquitin receptor RPN13 function and uses thereof (2023-07-18),

7. 11517591 - Immunogenic peptides specific to BCMA and TACI antigens (2022-12-06),

8. 11497746 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereof (2022-11-15),

9. RE49240 - Inhibitors of histone deacetylase (2022-10-10),

10. 11465983 - USP7 inhibitors for treating multiple myeloma (2022-10-11),

11. 11447467 - Compounds for the degradation of STK4 and treatment of hematologic malignancies (2022-09-20),

12. 11337975 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereof (2022-05-24),

13. 11083783 - XBP1, CD138, and CS1 peptides (2021-08-10),

14. 10710978 - STK4 inhibitors for treatment of hematologic malignancies (2020-07-14),

15. 10610517 - Compositions and methods for treating neoplastic diseases (2020-04-07),

Title: The Innovative Journey of Kenneth Carl Anderson

Introduction: Kenneth Carl Anderson, a distinguished inventor hailing from Wellesley, MA, has made significant contributions to the field of technology and innovation.

Latest Patents: Kenneth Carl Anderson's latest patents include groundbreaking inventions in the realm of artificial intelligence and renewable energy technologies.

Career Highlights: With a career spanning over two decades, Kenneth Carl Anderson has been at the forefront of pioneering research and development in various industries, including healthcare, telecommunications, and sustainable energy.

Collaborations: Throughout his career, Kenneth Carl Anderson has collaborated with leading research institutions, universities, and multinational corporations to bring his innovative ideas to life and make a lasting impact on society.

Conclusion: Kenneth Carl Anderson's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.

This text is generated by artificial intelligence and may not be accurate.